In contrast to enzymatic activation, conformational C5 activation cannot be prevented by eculizumab, explaining the residual hemolysis observed in PNH patients treated with adequate levels of this C5 inhibitor5. This evidence concerns the gene C5 and paroxysmal nocturnal hemoglobinuria.